296 related articles for article (PubMed ID: 16124003)
21. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
Fu X; Tao L; Zhang X
Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
[TBL] [Abstract][Full Text] [Related]
22. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16.
Griffith C; Noonan S; Lou E; Shillitoe EJ
Cancer Gene Ther; 2007 Dec; 14(12):985-93. PubMed ID: 17853922
[TBL] [Abstract][Full Text] [Related]
23. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.
Antoszczyk S; Spyra M; Mautner VF; Kurtz A; Stemmer-Rachamimov AO; Martuza RL; Rabkin SD
Neuro Oncol; 2014 Aug; 16(8):1057-66. PubMed ID: 24470552
[TBL] [Abstract][Full Text] [Related]
24. Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma.
Yang WQ; Senger D; Muzik H; Shi ZQ; Johnson D; Brasher PM; Rewcastle NB; Hamilton M; Rutka J; Wolff J; Wetmore C; Curran T; Lee PW; Forsyth PA
Cancer Res; 2003 Jun; 63(12):3162-72. PubMed ID: 12810644
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1.
Chai G; Liu N; Ma J; Li H; Oblinger JL; Prahalad AK; Gong M; Chang LS; Wallace M; Muir D; Guha A; Phipps RJ; Hock JM; Yu X
Cancer Sci; 2010 Sep; 101(9):1997-2004. PubMed ID: 20550523
[TBL] [Abstract][Full Text] [Related]
26. Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.
Jackson JD; McMorris AM; Roth JC; Coleman JM; Whitley RJ; Gillespie GY; Carroll SL; Markert JM; Cassady KA
Gene Ther; 2014 Nov; 21(11):984-90. PubMed ID: 25119379
[TBL] [Abstract][Full Text] [Related]
27. An HSV-2-based oncolytic virus deleted in the PK domain of the ICP10 gene is a potent inducer of apoptotic death in tumor cells.
Fu X; Tao L; Zhang X
Gene Ther; 2007 Aug; 14(16):1218-25. PubMed ID: 17538637
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.
Naito S; Obayashi S; Sumi T; Iwai S; Nakazawa M; Ikuta K; Yura Y
Cancer Gene Ther; 2006 Aug; 13(8):780-91. PubMed ID: 16645620
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
[TBL] [Abstract][Full Text] [Related]
30. In vitro studies of pigment epithelium-derived factor in human Schwann cells after treatment with axolemma-enriched fraction.
Lertsburapa T; De Vries GH
J Neurosci Res; 2004 Mar; 75(5):624-31. PubMed ID: 14991838
[TBL] [Abstract][Full Text] [Related]
31. Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication.
Mahller YY; Sakthivel B; Baird WH; Aronow BJ; Hsu YH; Cripe TP; Mehrian-Shai R
Cancer Gene Ther; 2008 Nov; 15(11):733-41. PubMed ID: 18551144
[TBL] [Abstract][Full Text] [Related]
32. A genetically engineered influenza A virus with ras-dependent oncolytic properties.
Bergmann M; Romirer I; Sachet M; Fleischhacker R; García-Sastre A; Palese P; Wolff K; Pehamberger H; Jakesz R; Muster T
Cancer Res; 2001 Nov; 61(22):8188-93. PubMed ID: 11719449
[TBL] [Abstract][Full Text] [Related]
33. Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB.
Dang I; DeVries GH
J Neurosci Res; 2005 Feb; 79(3):318-28. PubMed ID: 15602756
[TBL] [Abstract][Full Text] [Related]
34. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma.
Li H; Dutuor A; Tao L; Fu X; Zhang X
Clin Cancer Res; 2007 Jan; 13(1):316-22. PubMed ID: 17200370
[TBL] [Abstract][Full Text] [Related]
35. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
36. Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway.
Eisenberg DP; Carpenter SG; Adusumilli PS; Chan MK; Hendershott KJ; Yu Z; Fong Y
Surgery; 2010 Aug; 148(2):325-34. PubMed ID: 20633729
[TBL] [Abstract][Full Text] [Related]
37. The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells.
Fischer-Huchzermeyer S; Dombrowski A; Hagel C; Mautner VF; Schittenhelm J; Harder A
Am J Pathol; 2017 Jul; 187(7):1623-1632. PubMed ID: 28502478
[TBL] [Abstract][Full Text] [Related]
38. Herpes simplex virus 1 (HSV-1) for cancer treatment.
Shen Y; Nemunaitis J
Cancer Gene Ther; 2006 Nov; 13(11):975-92. PubMed ID: 16604059
[TBL] [Abstract][Full Text] [Related]
39. Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients.
Frahm S; Mautner VF; Brems H; Legius E; Debiec-Rychter M; Friedrich RE; Knöfel WT; Peiper M; Kluwe L
Neurobiol Dis; 2004 Jun; 16(1):85-91. PubMed ID: 15207265
[TBL] [Abstract][Full Text] [Related]
40. STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells.
Jackson JD; Markert JM; Li L; Carroll SL; Cassady KA
Mol Cancer Res; 2016 May; 14(5):482-92. PubMed ID: 26883073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
